Free Oncology CME

This brief accredited CME activity uses a quiz-based microlearning platform to present a patient case scenario and related questions, allowing clinicians to quickly test their knowledge of the essential components of evaluating patients with metastatic colorectal cancer to the liver and selecting an appropriate treatment strategy. They can then compare their responses with those of their peers. Rationale for correct answers and key educational takeaways are provided via video clips from expert faculty.

In this MedX activity, Robert Haddad, MD, explores the latest clinical data for emerging novel therapies for recurrent/metastatic head and neck squamous cell carcinoma with an emphasis on results presented at ESMO 2025.

Expert faculty dive into the rapidly evolving world of BCMA-directed bispecific antibodies for multiple myeloma, exploring practical strategies to bring these cutting-edge therapies into everyday clinical care.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Faculty discusses the prevention and management of cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and infections in patients with relapsed/refractory multiple myeloma treated with BCMA-directed bispecific antibodies.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Discover how communities of practice are expanding access to bispecific antibodies, as faculty share practical guidance on starting these therapies in community settings and smoothly transitioning patients from academic centers to local care.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Patient advocate and HealthTree Foundation CEO Jenny Ahlstrom shares fresh survey insights into the physical, emotional, and social quality-of-life experiences of patients treated with bispecific antibodies, while spotlighting key educational, financial, and community resources designed to support them.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.